Cytomed therapeutics limitedGDTC.US Overview
GDTC Overall Performance
GDTC AI Analysis & Strategy
GDTC Recent Performance
-6.48%
Cytomed therapeutics limited
0.81%
Avg of Sector
-1.14%
S&P500
GDTC PowerScanner
GDTC Key Information
GDTC Valuation Metrics
GDTC Earnings Table
GDTC Profile
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.